An Open-Label Study Of Lamictal In Neurotic Excoriation

Exclusion Criteria

• •unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination
• •history of seizures
• •myocardial infarction within 6 months
• •current pregnancy or lactation, or inadequate contraception in women of childbearing potential
• •a need for medication other than Lamictal with possible psychotropic effects or unfavorable interactions with Lamictal
• •clinically significant suicidality
• •lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder
• •current or recent (past 3 months) DSM-IV substance abuse or dependence
• •illegal substance use within 2 weeks of study initiation
• •initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline
• •previous treatment with Lamictal
• •treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
• •current treatment with an anti-epileptic medication and
• •patients who have previously been diagnosed with a medical condition that cause skin itchiness (e.g. liver, kidney, and blood diseases, etopic allergies)